Image Source: Pixabay
 

Aurora Cannabis (ACB) dropped 20.4% on June 18 despite reporting record fiscal 2025 results in its Q4 financial report (see here)—and here’s why:

1. Cautious Q1 guidance spooked investors: While Aurora posted strong Q4 numbers—like a 48% jump in medical cannabis revenue and positive free cash flow—it warned that international sales would dip in Q1 2026 due to short-term issues in Poland and the UK. That guidance overshadowed the upbeat results. CEO Miguel Martin, however, called the selloff an “overreaction,” emphasizing that the company remains debt-free, cash-flow positive, and focused on high-margin medical markets like Germany and Australia.
2. Earnings miss on the bottom line: Aurora reported a loss of 24 cents per share, missing analyst expectations of an 11-cent profit. Even with revenue beating estimates, the earnings miss raised concerns about near-term profitability.
3. Profit-taking after a strong run: The stock closed at $5.88 on June 17th (up 38.5% YTD) and fell by $1.00/share (17%) within minutes of the market trading on June 18th so some investors used the earnings event as a chance to lock in gains—especially with no immediate catalysts on the horizon.
    

About Aurora Cannabis

Aurora Cannabis Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. Specifically, it cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, dried flowers, vapes, dried milled strains, edibles, concentrates, and strain specific cannabis oils and extracts.
 

Aurora Cannabis Analyst Stock Forecasts and Ratings

Currently there is no analyst price target forecast available for Aurora Cannabis but 1 analyst rates ACB as a "Hold" suggesting that ACB is likely to perform similarly to the overall market.

More By This Author:

Micron Technology Continues To Surge: Up Another 22% Already In June - Here's Why
Recursion Pharmaceuticals Went Down 10% Week-Ending June 13th - Here's Why
Update: Abcellera Biologics Now Up 58% MTD